Skip to main content
MJH Life Sciences
  • Login
  • Register
  • Login
  • Register
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences
MJH Life Sciences

SUBSCRIBE: Print / eNewsletter

Diagnosis of Gastric GIST with Synchronous Gastric Cancer Often Missed

  • Leah Lawrence
February 18, 2014
  • Gastrointestinal Stromal Tumor, Gastrointestinal Cancer
Gastric GIST showing a prominent spindle cell proliferation.

The preoperative diagnosis of combined gastric gastrointestinal stromal tumor (GIST) and gastric cancer is often missed, according to the results of a recent study. However, the research also showed that a patient’s survival often depended on the treatment of the gastric cancer, indicating that active treatment of the gastric cancer could improve patient outcomes.

GIST has a relatively low incidence, but in many cases patients with GIST also present with other synchronous malignancies.

“Since the first report of synchronous epithelial and stromal tumors in the stomach in 2000, many patients with gastric GIST and synchronous gastric cancer have been described, most in single case studies,” wrote Mi Lin, MD, of Fujian Medical University Union Hospital, China, and colleagues. “However, little is known about the synchronous GIST and gastric cancer.”

In an attempt to identify characteristics and prognostic factors, Lin and colleagues conducted a retrospective study of 170 patients with gastric GIST who had undergone surgical resection of their disease between 2000 and 2011. The results were published in the World Journal of Surgical Oncology.

The 42 patients who had synchronous gastric cancer (24.7%) were classified as the CA Group; the 128 patients who did not were the non-CA Group. Patients in the CA Group were more likely to present with symptoms compared with patients in the non-CA Group (P < .05). The most commonly occurring symptoms included abdominal tenderness, black stool, abdominal distension and weight loss. The rate of preoperative diagnosis was 2.4% in the CA group compared with 97.6% in the non-CA group.

“In patients with simultaneous gastric cancer and gastric GIST, the symptoms of gastric GIST were often masked by the clinical symptoms of gastric cancer,” the researchers wrote. In many cases, the GISTs were small and were submucosal, muscular, or subserosal making them difficult to diagnosis.

The 3-year survival was 87% for the whole cohort; the 5-year survival was 82.3%. Patients in the CA group had a 3-year survival of 62.6% and a 5-year survival of 57.8%. In contrast, patients in the non-CA group had a 3-year survival of 94.8% and a 5-year survival of 90.1%, a statistically significant difference from that seen in the CA group.

Looking at patient characteristics, the researchers found that patient age, risk stratification, postoperative oral imatinib, and synchronous gastric cancer were all predictive of survival (P < .05 for all).

“The 5-year survival rates were significantly lower among patients with synchronous gastric cancer, both among patients stratified as being at very low risk and among those stratified as being at intermediate risk/high risk,” the researchers wrote.

Related Articles

  • Patient Navigation Effective in Screening Colonoscopy Rate for CRC in Latino Groups
  • FDA Grants Priority Review to Pemigatinib for Subgroup
  • Risk Tool Shows Promise for Predicting Adverse Opioid-Related Outcomes in Cancer Survivors
  • Active Choice Intervention in EHR Is Effective for Clinician Ordering of Screening Tests
  • What Are the Most Common Esophageal Metastases

Resource Topics rightRail

  • Resource Topics
  • Partner Content
  • Breast Cancer
  • Acute Myeloid Leukemia
  • HER2-Positive Breast Cancer
  • Videos Breast Cancer
  • Follicular Lymphoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

ONCOLOGY Vol 33 No 11
Nov 21, 2019 Vol 33 No 11
Subscribe
Connect with Us
  • Column 1
    • Home
    • About Us
    • Contact Us
  • Column 2
    • Editorial Info
    • Editorial Board
  • Column 3
    • Advertising Info
    • Reprints
    • Advertising Terms
  • Column 4
    • Terms of Use
    • Privacy Policy
Modern Medicine Network
© UBM 2019, All rights reserved.
Reproduction in whole or in part is prohibited.

We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".